Irinotecan

Drug Profile

Irinotecan

Alternative Names: Campotesin; Campto; Camptosar; CPT-11; DQ 2805; IHL-305; Irinotecan hydrochloride; Irinotecan liposome injection; Irinotecan semi-solid matrix; Irinotecan SSM; Irkan; Irnocam; SN 38B11; Topotecin; U 101440E

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Yakult Honsha
  • Developer Daiichi Sankyo Company; Pfizer; Sanofi; Yakult Honsha
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Cervical cancer; Colorectal cancer; Gastrointestinal cancer; Leukaemia; Lung cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Skin cancer; Small cell lung cancer; Solid tumours; Uterine cancer
  • Discontinued Mesothelioma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Liposomal)
  • 20 Dec 2013 Launched for Pancreatic cancer (unresectable) in Japan (IV)
  • 20 Dec 2013 Launched for Solid tumours (in children) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top